AI Article Synopsis
- The study evaluated the effectiveness and safety of bimekizumab for treating psoriasis through a systematic review of randomized controlled trials (RCTs)!
- A total of six studies with 1252 participants showed that bimekizumab significantly improved psoriasis symptoms (like PASI scores) compared to a placebo group, with various levels of improvement reported!
- Results indicated that bimekizumab has a good safety profile, as there were no significant differences in adverse events between the bimekizumab and placebo groups!
Article Abstract
Aim: This study aimed to evaluate the efficacy and safety of bimekizumab for psoriasis.
Methods: The PubMed, Web of Science, Cochrane Library, and Embase databases were systematically searched until November 20, 2022, to identify randomized controlled trials (RCTs) reporting the efficacy and safety of bimekizumab. The identified studies were screened according to inclusion and exclusion criteria, and a meta-analysis was performed on the selected studies using the Stata (version 17.0) software to investigate the efficacy and safety of bimekizumab.
Results: Six studies involving 1252 participants were considered. Compared with the control group which received placebo, the bimekizumab group had a larger number of patients with improvement in Psoriasis Area and Severity Index (PASI) of at least 75% (PASI75) (RR: 20.54, 95%CI: 12.41-33.99; = .000), at least 90% (PASI90) (RR:16.99, 95%CI: 7.09-40.68; = .000) and 100%(PASI100) (RR:14.57; 95%CI: 5.26-40.35; = .000) and a larger number with improvement in Investigator Global Assessment (IGA) response (RR:22.57; 95%CI: 12.74-39.98; = .000). There was no obvious difference between the bimekizumab and placebo groups in treatment of emergent adverse events (TEAEs) (RR:1.17; 95%CI: 0.93-1.47; > .05) and serious TEAEs (RR: 0.67; 95%CI: 0.28-1.61; > .05).
Conclusions: Bimekizumab shows promising efficacy for the treatment of psoriasis with favorable safety records.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09546634.2023.2199106 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating Efficacy and Safety of Crisaborole in Managing Childhood Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-Analysis.
Br J Hosp Med (Lond)
January 2025
Department of Pediatrics, Taizhou Women and Children's Hospital, Taizhou, Zhejiang, China.
Atopic dermatitis (AD) is a common chronic inflammatory skin disorder globally. Crisaborole, a nonsteroidal topical phosphodiesterase 4 inhibitor (PDE4i), has been utilized in treating AD. Crisaborole regulates the production of inflammatory cytokines, which are usually overactive among AD patients.
View Article and Find Full Text PDFOnce-Weekly Insulin: A Breakthrough in Diabetes Management or an Unresolved Challenge?
Br J Hosp Med (Lond)
January 2025
Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
The advent of once-weekly insulin icodec is a promising development in the care of individuals with diabetes. These once-weekly formulations aimed to improve patient adherence and quality of life for patients who find daily injection administration challenging. Insulin icodec has demonstrated comparable glycemic control to conventionally used daily basal insulins, such as insulin glargine and degludec, in the ONWARDS clinical trials.
View Article and Find Full Text PDFComparison of Different Thromboprophylaxis Regimens in Elderly Patients Following Hip Arthroplasty.
Br J Hosp Med (Lond)
January 2025
Department of Osteoarthritis, Yantai City Yantai Shan Hospital, Yantai, Shandong, China.
Deep venous thrombosis (DVT) represents a significant postoperative complication after artificial femoral head replacement, with the incidence increasing proportionally with patient age. This study aimed to evaluate the effect of early postoperative use of intermittent pneumatic compression devices (IPC), followed by the combined use of low molecular weight heparin (LMWH) after 48 hours, for the prevention of postoperative lower limb DVT in elderly patients undergoing hip arthroplasty. The retrospective study included 100 elderly patients who underwent unilateral femoral head replacement.
View Article and Find Full Text PDFAn Iterative Design Method for Advancing Air Traffic Control and Management Training Through Immersive VFR 3D Map Visualization.
IISE Trans Occup Ergon Hum Factors
January 2025
The Bradley Department of Electrical and Computer Engineering, College of Engineering, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.
OCCUPATIONAL APPLICATIONSInnovative tools that align with modern learners' preferences are essential for training in safety-critical professions like Air Traffic Control/Management. This study evaluated a Virtual Reality Visual Flight Rules 3D Map Visualization Tool designed to meet the Federal Aviation Administration's (FAA) modernization goals. The tool immerses trainee in contextually accurate environments, enhancing engagement and self-paced learning.
View Article and Find Full Text PDFFenestrated Anaconda Endograft for the Treatment of Complex Aortic Aneurysms: Systematic Review and Meta-Analysis.
J Endovasc Ther
January 2025
Department of Vascular Surgery, Swiss Aortic Center Bern, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland.
Purpose: To perform a systematic review and meta-analysis of the outcomes of Anaconda fenestrated endograft for the treatment of complex abdominal aortic aneurysms (cAAA).
Material And Methods: A systematic search of all the literature reported until May 2024 was performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. The pooled 30-day mortality rate, technical success rate, reintervention rate as well as bridging stent occlusion rate, and corresponding 95% confidence intervals (CIs) were estimated using fixed or random effect methods.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!